Literature DB >> 19553198

International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia.

M E Faughnan1, V A Palda, G Garcia-Tsao, U W Geisthoff, J McDonald, D D Proctor, J Spears, D H Brown, E Buscarini, M S Chesnutt, V Cottin, A Ganguly, J R Gossage, A E Guttmacher, R H Hyland, S J Kennedy, J Korzenik, J J Mager, A P Ozanne, J F Piccirillo, D Picus, H Plauchu, M E M Porteous, R E Pyeritz, D A Ross, C Sabba, K Swanson, P Terry, M C Wallace, C J J Westermann, R I White, L H Young, R Zarrabeitia.   

Abstract

BACKGROUND: HHT is an autosomal dominant disease with an estimated prevalence of at least 1/5000 which can frequently be complicated by the presence of clinically significant arteriovenous malformations in the brain, lung, gastrointestinal tract and liver. HHT is under-diagnosed and families may be unaware of the available screening and treatment, leading to unnecessary stroke and life-threatening hemorrhage in children and adults.
OBJECTIVE: The goal of this international HHT guidelines process was to develop evidence-informed consensus guidelines regarding the diagnosis of HHT and the prevention of HHT-related complications and treatment of symptomatic disease.
METHODS: The overall guidelines process was developed using the AGREE framework, using a systematic search strategy and literature retrieval with incorporation of expert evidence in a structured consensus process where published literature was lacking. The Guidelines Working Group included experts (clinical and genetic) from eleven countries, in all aspects of HHT, guidelines methodologists, health care workers, health care administrators, HHT clinic staff, medical trainees, patient advocacy representatives and patients with HHT. The Working Group determined clinically relevant questions during the pre-conference process. The literature search was conducted using the OVID MEDLINE database, from 1966 to October 2006. The Working Group subsequently convened at the Guidelines Conference to partake in a structured consensus process using the evidence tables generated from the systematic searches.
RESULTS: The outcome of the conference was the generation of 33 recommendations for the diagnosis and management of HHT, with at least 80% agreement amongst the expert panel for 30 of the 33 recommendations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19553198     DOI: 10.1136/jmg.2009.069013

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  237 in total

1.  Decreased levels of miR-28-5p and miR-361-3p and increased levels of insulin-like growth factor 1 mRNA in mononuclear cells from patients with hereditary hemorrhagic telangiectasia 1.

Authors:  Anthony Cannavicci; Qiuwang Zhang; Si-Cheng Dai; Marie E Faughnan; Michael J B Kutryk
Journal:  Can J Physiol Pharmacol       Date:  2018-12-04       Impact factor: 2.273

2.  Basal Ganglia T1 Hyperintensity in Hereditary Hemorrhagic Telangiectasia.

Authors:  A Parvinian; V N Iyer; B S Pannu; D R Apala; C P Wood; W Brinjikji
Journal:  AJNR Am J Neuroradiol       Date:  2017-08-03       Impact factor: 3.825

Review 3.  Bleeding and clotting in hereditary hemorrhagic telangiectasia.

Authors:  Christopher Dittus; Michael Streiff; Jack Ansell
Journal:  World J Clin Cases       Date:  2015-04-16       Impact factor: 1.337

4.  Prevalence and predictors of anemia in hereditary hemorrhagic telangiectasia.

Authors:  Raj S Kasthuri; Megan Montifar; Jeffrey Nelson; Helen Kim; Michael T Lawton; Marie E Faughnan
Journal:  Am J Hematol       Date:  2017-06-22       Impact factor: 10.047

Review 5.  Diagnosis and Treatment of Hereditary Hemorrhagic Telangiectasia.

Authors:  Cameron Grigg; Daniel Anderson; James Earnshaw
Journal:  Ochsner J       Date:  2017

Review 6.  ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.

Authors:  Sapna Syngal; Randall E Brand; James M Church; Francis M Giardiello; Heather L Hampel; Randall W Burt
Journal:  Am J Gastroenterol       Date:  2015-02-03       Impact factor: 10.864

7.  Hereditary Hemorrhagic Telangiectasia: Breakpoint Characterization of a Novel Large Deletion in ACVRL1 Suggests the Causing Mechanism.

Authors:  Laura Boeri; Orietta Radi; Cecilia Canzonieri; Elisabetta Buscarini; Agnese Scatigno; Antonella Minelli; Federica Ornati; Fabio Pagella; Cesare Danesino; Carla Olivieri
Journal:  Mol Syndromol       Date:  2013-02-28

8.  Identification of Retinal Vascular Lesions Using Ultra-Widefield Angiography in Hereditary Hemorrhagic Telangiectasia Patients.

Authors:  Sampat Sindhar; Bliss E O'Bryhim; Jordan Licata; Jay F Piccirillo; Rajendra S Apte
Journal:  Ophthalmol Retina       Date:  2019-02-15

9.  The ACVRL1 c.314-35A>G polymorphism is associated with organ vascular malformations in hereditary hemorrhagic telangiectasia patients with ENG mutations, but not in patients with ACVRL1 mutations.

Authors:  Ludmila Pawlikowska; Jeffrey Nelson; Diana E Guo; Charles E McCulloch; Michael T Lawton; William L Young; Helen Kim; Marie E Faughnan
Journal:  Am J Med Genet A       Date:  2015-04-02       Impact factor: 2.802

10.  Cerebrovascular complications in a patient with hereditary hemorrhagic telangiectasia (HHT, Rendu-Osler disease).

Authors:  M Meier; S Greschus; H H Schild; D R Hadizadeh
Journal:  Clin Neuroradiol       Date:  2014-02-14       Impact factor: 3.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.